Subscribe for the newsletter
Sign in
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Press Releases
Sort By
Newest First
1 / 153
1 / 153
Clinical Trials
EXUMA Biotech Announces Phase 1 Results for its Autologous HER2 Directed CAR-T Product at ASCO GI 2025
EXUMA Biotechnology
PR-01-25-NI-26
Jan 24, 2025
FDA
Clarity Receives U.S. FDA Fast Track Designation for Cu-64 SAR-bisPSMA in Biochemical Recurrence of Prostate Cancer
Clarity
PR-01-25-NI-25
Jan 24, 2025
Extension
Sapient Teams with Alamar Biosciences to Advance Proteomics Using NULISA™ Assays for Cytokines, Chemokines, and Inflammation
Sapient
PR-01-25-NI-24
Jan 21, 2025
Clinic
Chromatin Bioscience's Synthetic Promoter Supports EsoBiotec's ESO-T01 CAR-T Therapy As It Enters the Clinic
Chromatin Bioscience
PR-01-25-NI-23
Jan 20, 2025
Announcement
NorthX Biologics Appoints Patrick DePalma Senior Vice President of North American Business Development
NorthX Biologics
PR-01-25-NI-22
Jan 20, 2025
Announcement
Caris Life Sciences Strategically Collaborates with Ontada to Advance Oncology Research and the Adoption of Precision Medicine
Caris Life Sciences
PR-01-25-NI-21
Jan 20, 2025
DPX
BioVaxys Developing DPX to be the Carrier of Choice for mRNA Vaccines, a Market Projected to Grow to USD$48,000,000,000 by 2030
BioVaxys Technology Corp
PR-01-25-NI-20
Jan 17, 2025
FDA
Axcynsis Therapeutics Receives FDA Clearance for IND Application of AT03-65 Powered by AxcynDOT™ Technology
Axcynsis Therapeutics
PR-01-25-NI-19
Jan 16, 2025
Clinical CRO
Regulatory Approval Clears Path for Oncolytics Biotech to Pancreatic Cancer Treatment
Oncolytics Biotech
PR-01-25-NI-18
Jan 16, 2025
Business
Samsung Biologics presents business updates at 2025 J.P. Morgan Healthcare Conference
Samsung Biologics
PR-01-25-NI-17
Jan 16, 2025
Clinical Trials
Gene Therapeutics (NGGT) Announces Publication of Early Clinical Trial Results for the Treatment of Bietti's Crystalline Dystrophy
NGGT Inc.
PR-01-25-NI-16
Jan 16, 2025
Announcement
Moffitt Cancer Center and Cryoport Announce Strategic Collaboration
Cryoport
PR-01-25-NI-15
Jan 16, 2025
Acquirement
Lilly to Acquire Scorpion Therapeutics' Mutant-Selective PI3Kα Inhibitor Program
Eli Lilly and Company
PR-01-25-NI-14
Jan 14, 2025
Syringe
Vetter Introduces the Next Evolution of the V-OVS® Syringe Closure System
Vetter Pharma International GmbH
PR-01-25-NI-13
Jan 14, 2025
Peptide
BioDuro Opens New Solid-Phase Peptide Synthesis Scale-up Facility
BioDuro
PR-01-25-NI-11
Jan 14, 2025
Drug Development
REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases
REGENXBIO
PR-01-25-NI-12
Jan 14, 2025
Clinical CRO
HyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma
Soligenix, Inc.
PR-01-25-NI-10
Jan 14, 2025
Announcement
Servier Expands Tibsovo (ivosidenib) Program to Study Safety and Efficacy in IDH1-Mutated Hematologic and Solid Tumor Cancers
Servier Pharmaceuticals
PR-01-25-NI-09
Jan 14, 2025
Announcement
Ultima Genomics Announces UG 100™ Sequencing Platform Selected for UK Biobank's Groundbreaking Human Proteome Study
Ultima Genomics
PR-01-25-NI-08
Jan 10, 2025
Antibody
Timberlyne Therapeutics Secures $180M Series A to Advance CM313, a Promising Anti-CD38 Antibody for High-Need Diseases.
Timberlyne Therapeutics
PR-01-25-NI-07
Jan 10, 2025
